Patients Enrolled in Large Randomized Clinical Trials of Antiplatelet Treatment for Prevention After Transient Ischemic Attack or Ischemic Stroke Are Not Representative of Patients in Clinical Practice: the Netherlands Stroke Survey

Background and Purpose—Many randomized clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of new vascular events in patients with a recent transient ischemic attack or ischemic stroke. Evidence from these trials forms the basis for national and international guidelines for the management of nearly all such patients in clinical practice. However, abundant and strict enrollment criteria may limit the validity and the applicability of results of randomized clinical trials to clinical practice. We estimated the eligibility for participation in la... Mehr ...

Verfasser: Maasland, E. (Lisette)
Oostenbrugge, R.J. (Robert Jan) van
Franke, C.L. (Cees)
Scholte op Reimer, W.J.M. (Wilma)
Koudstaal, P.J. (Peter)
Dippel, D.W.J. (Diederik)
Dokumenttyp: Artikel
Erscheinungsdatum: 2009
Schlagwörter: Aged / Data Collection/methods / Female / Follow-Up Studies / Humans / Ischemic Attack / Transient/drug therapy/mortality / Male / Middle Aged / Netherlands/epidemiology / Platelet Aggregation Inhibitors/therapeutic use / Prospective Studies / RCT / Randomized Controlled Trials as Topic/methods / Secondary Prevention/methods / Stroke/drug therapy/mortality / antiplatelet drugs / survey
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29199092
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://repub.eur.nl/pub/22401

Background and Purpose—Many randomized clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of new vascular events in patients with a recent transient ischemic attack or ischemic stroke. Evidence from these trials forms the basis for national and international guidelines for the management of nearly all such patients in clinical practice. However, abundant and strict enrollment criteria may limit the validity and the applicability of results of randomized clinical trials to clinical practice. We estimated the eligibility for participation in landmark trials of antiplatelet drugs of an unselected group of patients with stroke or transient ischemic attack from a national stroke survey. Methods—Nine hundred seventy-two patients with transient ischemic att